Medtronic (MDT) Revenue & Revenue Breakdown
Medtronic Revenue Highlights
Latest Revenue (Y)
$32.36B
Latest Revenue (Q)
$7.92B
Main Segment (Y)
Cardiac and Vascular Group
Main Geography (Y)
Japan, Australia, New Zealand, Korea, Canada, and Western Europe
Medtronic Revenue by Period
Medtronic Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-04-26 | $32.36B | 3.64% |
| 2023-04-28 | $31.23B | -1.45% |
| 2022-04-29 | $31.69B | 5.21% |
| 2021-04-30 | $30.12B | 4.16% |
| 2020-04-24 | $28.91B | -5.38% |
| 2019-04-26 | $30.56B | 2.02% |
| 2018-04-27 | $29.95B | 0.82% |
| 2017-04-28 | $29.71B | 3.04% |
| 2016-04-29 | $28.83B | 42.31% |
| 2015-04-24 | $20.26B | 19.15% |
| 2014-04-30 | $17.00B | 2.50% |
| 2013-04-30 | $16.59B | 2.51% |
| 2012-04-30 | $16.18B | 1.58% |
| 2011-04-30 | $15.93B | 0.73% |
| 2010-04-30 | $15.82B | 8.34% |
| 2009-04-30 | $14.60B | 8.02% |
| 2008-04-30 | $13.52B | 9.89% |
| 2007-04-30 | $12.30B | 8.92% |
| 2006-04-30 | $11.29B | 12.31% |
| 2005-04-30 | $10.05B | 10.65% |
| 2004-04-30 | $9.09B | 18.55% |
| 2003-04-30 | $7.67B | 19.57% |
| 2002-04-30 | $6.41B | 15.47% |
| 2001-04-30 | $5.55B | 10.71% |
| 2000-04-30 | $5.01B | 21.30% |
| 1999-04-30 | $4.13B | 58.71% |
| 1998-04-30 | $2.60B | 6.83% |
| 1997-04-30 | $2.44B | 12.41% |
| 1996-04-30 | $2.17B | 24.49% |
| 1995-04-30 | $1.74B | 25.27% |
| 1994-04-30 | $1.39B | - |
Medtronic generated $32.36B in revenue during NA 2024, up 3.64% compared to the previous quarter, and up 105.91% compared to the same period a year ago.
Medtronic Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-07-26 | $7.92B | -7.85% |
| 2024-04-26 | $8.59B | 6.18% |
| 2024-01-26 | $8.09B | 1.32% |
| 2023-10-27 | $7.98B | 3.66% |
| 2023-07-28 | $7.70B | -9.85% |
| 2023-04-28 | $8.54B | 10.57% |
| 2023-01-27 | $7.73B | 1.87% |
| 2022-10-28 | $7.58B | 2.90% |
| 2022-07-29 | $7.37B | -8.88% |
| 2022-04-29 | $8.09B | 4.20% |
| 2022-01-28 | $7.76B | -1.07% |
| 2021-10-29 | $7.85B | -1.75% |
| 2021-07-30 | $7.99B | -2.45% |
| 2021-04-30 | $8.19B | 5.31% |
| 2021-01-29 | $7.78B | 1.67% |
| 2020-10-30 | $7.65B | 17.52% |
| 2020-07-31 | $6.51B | 8.49% |
| 2020-04-24 | $6.00B | -22.28% |
| 2020-01-24 | $7.72B | 0.14% |
| 2019-10-25 | $7.71B | 2.84% |
| 2019-07-26 | $7.49B | -8.02% |
| 2019-04-26 | $8.15B | 7.95% |
| 2019-01-25 | $7.55B | 0.87% |
| 2018-10-26 | $7.48B | 1.31% |
| 2018-07-27 | $7.38B | -9.33% |
| 2018-04-27 | $8.14B | 10.52% |
| 2018-01-26 | $7.37B | 4.52% |
| 2017-10-27 | $7.05B | -4.60% |
| 2017-07-28 | $7.39B | -6.64% |
| 2017-04-28 | $7.92B | 8.69% |
| 2017-01-27 | $7.28B | -0.84% |
| 2016-10-28 | $7.34B | 2.50% |
| 2016-07-29 | $7.17B | -5.30% |
| 2016-04-29 | $7.57B | 9.13% |
| 2016-01-29 | $6.93B | -1.76% |
| 2015-10-30 | $7.06B | -2.97% |
| 2015-07-31 | $7.27B | -0.41% |
| 2015-04-24 | $7.30B | 69.15% |
| 2015-01-23 | $4.32B | -1.10% |
| 2014-10-31 | $4.37B | 2.18% |
| 2014-07-31 | $4.27B | -6.40% |
| 2014-04-30 | $4.57B | 9.66% |
| 2014-01-31 | $4.16B | -0.74% |
| 2013-10-31 | $4.19B | 2.72% |
| 2013-07-31 | $4.08B | -8.45% |
| 2013-04-30 | $4.46B | 10.75% |
| 2013-01-31 | $4.03B | -1.66% |
| 2012-10-31 | $4.09B | 2.17% |
| 2012-07-31 | $4.01B | -6.73% |
| 2012-04-30 | $4.30B | 9.67% |
| 2012-01-31 | $3.92B | -5.18% |
| 2011-10-31 | $4.13B | 2.05% |
| 2011-07-31 | $4.05B | -5.73% |
| 2011-04-30 | $4.29B | 8.43% |
| 2011-01-31 | $3.96B | 1.49% |
| 2010-10-31 | $3.90B | 3.45% |
| 2010-07-31 | $3.77B | -10.08% |
| 2010-04-30 | $4.20B | 8.96% |
| 2010-01-31 | $3.85B | 0.34% |
| 2009-10-31 | $3.84B | -2.42% |
| 2009-07-31 | $3.93B | 2.72% |
| 2009-04-30 | $3.83B | 9.59% |
| 2009-01-31 | $3.49B | -2.13% |
| 2008-10-31 | $3.57B | -3.67% |
| 2008-07-31 | $3.71B | -3.99% |
| 2008-04-30 | $3.86B | 13.36% |
| 2008-01-31 | $3.40B | - |
Medtronic generated $7.92B in revenue during Q1 2025, up -7.85% compared to the previous quarter, and up 92.64% compared to the same period a year ago.
Medtronic Revenue Breakdown
Medtronic Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Apr 24 | Apr 23 | Apr 22 | Apr 21 | Apr 20 |
|---|---|---|---|---|---|
| Diabetes Group | $2.49B | $2.26B | - | - | - |
| Cardiac and Vascular Group | $11.83B | $11.57B | $5.06B | - | - |
| Medical Surgical | $8.42B | $8.43B | - | - | - |
| Neuroscience Group | $9.41B | $8.96B | - | - | - |
| Neuroscience Portfolio | - | $8.96B | $5.75B | $5.46B | - |
| Medical Surgical Portfolio | - | $8.43B | $3.86B | $3.65B | - |
| Diabetes Operating Unit | - | $2.26B | - | - | - |
| Cardiovascular | - | $11.57B | $5.54B | - | - |
| Cardiovascular Portfolio | - | - | - | $141.00M | - |
| Restorative Therapies Group | - | - | - | - | $5.12B |
| Minimally Invasive Therapies Group | - | - | - | - | $3.53B |
Medtronic's latest annual revenue breakdown by segment (product or service), as of Apr 24: Cardiac and Vascular Group (36.81%), Neuroscience Group (29.26%), Medical Surgical (26.19%), and Diabetes Group (7.74%).
Quarterly Revenue by Product
| Product/Service | Jul 24 | Apr 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuroscience Group | $2.32B | $4.90B | $2.29B | $4.44B | $1.51B | $1.51B | $1.42B | $1.40B | $1.39B | $1.45B | - | - | - | - | - | - | - | - | - | - |
| Diabetes Group | $647.00M | $947.00M | $963.00M | $1.16B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cardiac and Vascular Group | $3.01B | $6.06B | $1.27B | $1.38B | $1.21B | $880.00M | $1.37B | $1.46B | $1.36B | $1.51B | - | - | - | - | - | - | - | - | - | - |
| Medical Surgical | $2.00B | $4.24B | $2.14B | $4.08B | $965.00M | $905.00M | $843.00M | $990.00M | $970.00M | $990.00M | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | $22.00M | $32.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cardiovascular | - | - | $2.92B | $5.70B | $9.23B | $1.38B | $1.42B | $1.30B | $1.46B | $1.30B | $1.37B | $1.42B | - | - | - | - | - | - | - | - |
| Minimally Invasive Therapies Group | - | - | - | - | - | - | - | - | - | - | - | - | $959.00M | $996.00M | $722.00M | $763.00M | $934.00M | $922.00M | $913.00M | $971.00M |
| Restorative Therapies Group | - | - | - | - | - | - | - | - | - | - | - | - | $1.40B | $1.40B | $1.14B | $935.00M | $1.41B | $1.44B | $1.34B | $1.47B |
Medtronic's latest quarterly revenue breakdown by segment (product or service), as of Jul 24: Cardiac and Vascular Group (37.74%), Neuroscience Group (29.08%), Medical Surgical (25.05%), and Diabetes Group (8.12%).
Medtronic Revenue Breakdown by Country
Annual Revenue by Country
| Country | Apr 24 | Apr 23 | Apr 22 | Apr 21 | Apr 20 |
|---|---|---|---|---|---|
| Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea | $5.82B | $5.45B | - | - | - |
| Japan, Australia, New Zealand, Korea, Canada, and Western Europe | $9.98B | $9.41B | - | - | - |
| Total Other Countries, Excluding United States and Ireland | - | $14.76B | $15.45B | $14.49B | $13.91B |
| IRELAND | - | $98.00M | $101.00M | $100.00M | $85.00M |
| Total Other Countries, Excluding Ireland | - | $31.13B | $31.59B | $30.02B | $28.83B |
| Medical Surgical Portfolio | - | - | $3.86B | - | - |
| Neuroscience Portfolio | - | - | $5.75B | - | - |
| Cardiovascular | - | - | $5.54B | - | - |
Medtronic's latest annual revenue breakdown by geography, as of Apr 24: Japan, Australia, New Zealand, Korea, Canada, and Western Europe (63.15%), and Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea (36.85%).
Quarterly Revenue by Country
| Country | Jul 24 | Apr 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $4.08B | $4.18B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IRELAND | $30.00M | $29.00M | $29.00M | $27.00M | $23.00M | $25.00M | $23.00M | $25.00M | $24.00M | $27.00M | $26.00M | $26.00M | $25.00M | $24.00M | $24.00M | $19.00M | $22.00M | $23.00M | $20.00M | - |
| Middle East, Africa, Latin America, Eastern Europe, and Asia, Excluding Japan and Korea | - | $3.07B | $1.44B | $1.33B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Japan, Australia, New Zealand, Korea, Canada, and Western Europe | - | $5.15B | $2.37B | $2.67B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Countries, Excluding United States and Ireland | - | - | $3.78B | $3.75B | $4.04B | $3.64B | $3.49B | $3.58B | $3.97B | $3.80B | $3.82B | $3.86B | $3.98B | $3.81B | $3.57B | $3.13B | $3.13B | $3.67B | $3.55B | $3.56B |
| Total Other Countries, Excluding Ireland | - | - | $7.96B | $7.67B | $8.52B | $7.70B | $7.56B | $7.35B | $8.06B | $7.74B | $7.82B | $7.96B | $8.16B | $7.75B | $7.62B | $6.48B | $5.98B | $7.70B | $7.68B | $7.47B |
| Neuroscience Group | - | - | - | - | - | $1.51B | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cardiovascular | - | - | - | - | - | $1.38B | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Medical Surgical | - | - | - | - | - | $965.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Medtronic's latest quarterly revenue breakdown by geography, as of Jul 24: UNITED STATES (99.27%), and IRELAND (0.73%).
Medtronic Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.38B |
| MDT | Medtronic | $32.36B | $7.92B |
| SYK | Stryker | $20.50B | $5.42B |
| EW | Edwards Lifesciences | $6.00B | $1.39B |
| ALGN | Align | $3.86B | $1.03B |
| DXCM | DexCom | $3.62B | $1.00B |
| ZBH | Zimmer Biomet | $1.94B | $1.89B |
| PODD | Insulet | $1.70B | $488.50M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
MDT Revenue FAQ
What is Medtronic’s yearly revenue?
Medtronic's yearly revenue for 2024 was $32.36B, representing an increase of 3.64% compared to 2023. The company's yearly revenue for 2023 was $31.23B, representing a decrease of -1.45% compared to 2022. MDT's yearly revenue for 2022 was $31.69B, representing an increase of 5.21% compared to 2021.
What is Medtronic’s quarterly revenue?
Medtronic's quarterly revenue for Q1 2025 was $7.92B, a -7.85% decrease from the previous quarter (Q4 2024), and a 2.77% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $8.59B, a 6.18% increase from the previous quarter (Q3 2024), and a 0.53% increase year-over-year (Q4 2023). MDT's quarterly revenue for Q3 2024 was $8.09B, a 1.32% increase from the previous quarter (Q2 2024), and a 4.68% increase year-over-year (Q3 2023).
What is Medtronic’s revenue growth rate?
Medtronic's revenue growth rate for the last 3 years (2022-2024) was 2.14%, and for the last 5 years (2020-2024) was 11.94%.
What are Medtronic’s revenue streams?
Medtronic's revenue streams in r 24 are Diabetes Group, Cardiac and Vascular Group, Medical Surgical, and Neuroscience Group. Diabetes Group generated $2.49B in revenue, accounting 7.74% of the company's total revenue, up 9.99% year-over-year. Cardiac and Vascular Group generated $11.83B in revenue, accounting 36.81% of the company's total revenue, up 2.23% year-over-year. Medical Surgical generated $8.42B in revenue, accounting 26.19% of the company's total revenue, down -0.19% year-over-year. Neuroscience Group generated $9.41B in revenue, accounting 29.26% of the company's total revenue, up 4.99% year-over-year.
What is Medtronic’s main source of revenue?
For the fiscal year ending Apr 24, the largest source of revenue of Medtronic was Cardiac and Vascular Group. This segment made a revenue of $11.83B, representing 36.81% of the company's total revenue.